| Species |
Human |
| Protein Construction |
| His |
Avi |
NKG2D/CD314 (Phe78-Val216)
Accession # P26718 |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized NKG2D/CD314, His & Avi, Human at 1μg/ml (100μl/well) on the plate can bind AntiNKG2D Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
19.0 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 36-38 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
NKG2D is a type II transmembrane glycoprotein having an extracellular lectin-like domain. This domain lacks the recognizable calcium-binding sites found in true C-type lectins and binds protein rather than carbohydrate ligands. Human NKG2D is expressed on CD8 alpha beta T cells, gamma δ T cells, NK cells and NKT cells. |
| Synonyms |
CD314; D12S2489E; KLR; NKG2-D; NKG2D |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
